Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients.

ABSTRACT:

Background

Epirubicin/cyclophosphamide (EC) and docetaxel (D) are commonly used in a sequential regimen in the neoadjuvant treatment of early, high-risk or locally advanced breast cancer (BC). Novel approaches to increase the response rate combine this treatment with immunotherapies such as PD-1 inhibition. However, the expected stimulatory effect on lymphocytes may depend on the chemotherapy backbone. Therefore, we separately compared the immunomodulatory effects of EC and D in the setting of a randomized clinical trial.

Methods

Tumor and blood samples of 154 patients from the ABCSG-34 trial were available (76 patients received four cycles of EC followed by four cycles of D; 78 patients get the reverse treatment sequence). Tumor-infiltrating lymphocytes, circulating lymphoc

SUBMITTER: Wimmer K 

PROVIDER: S-EPMC10644559 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature